[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603568":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":37,"studyPopulation":37,"armGroups":44,"interventions":58,"overallOfficials":37,"centralContacts":75,"locations":81,"responsibleParty":100,"collaborators":37,"id":102,"slug":37,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":37,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":37,"enrollmentInfo":110,"targetDuration":37,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":37,"overallStatus":84,"whyStopped":37,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":37},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-free Survival (PFS)","PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first.","Up to 4 years",[14,17,20,23,26,30,33],{"measure":15,"description":16,"timeFrame":12},"Overall Response (Partial Response [PR] or Better)","Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.",{"measure":18,"description":19,"timeFrame":12},"Very Good Partial Response (VGPR) or Better Response","VGPR or better (Stringent Complete Response \\[sCR\\]+Complete Response \\[CR\\]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.",{"measure":21,"description":22,"timeFrame":12},"Complete Response (CR) or Better Response","CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria",{"measure":24,"description":25,"timeFrame":12},"Duration of Response (DOR)","DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever",{"measure":27,"description":28,"timeFrame":29},"Minimal Residual Disease (MRD) Negativity","MRD negativity is defined as participants who achieve MRD negativity at a threshold of 10\\^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy","Up to approximately 4 years",{"measure":31,"description":32,"timeFrame":12},"Number of Participants with Adverse Events (AEs) by Severity","Number of participants with AEs by Severity will be reported.",{"measure":34,"description":35,"timeFrame":36},"Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)","Change from baseline scores","Baseline up to 4 years",null,{"allocation":39,"interventionModel":40,"interventionModelDescription":37,"primaryPurpose":41,"observationalModel":37,"timePerspective":37,"maskingInfo":42},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":43,"maskingDescription":37,"whoMasked":37},"NONE",[45,51],{"label":46,"type":47,"description":48,"interventionNames":49},"QLS32015","EXPERIMENTAL","Participants will receive teclistamab monotherapy.",[50],"Drug: QLS32015",{"label":52,"type":47,"description":53,"interventionNames":54},"Pomalidomide, Dexamethasone (Pd) or Selinexor and Dexamethasone (Sd)","Participants will receive either Pd or Sd based on principal investigator's choice.",[55,56,57],"Drug: Pomalidomide","Drug: Selinexor","Drug: Dexamethasone",[59,63,67,71],{"type":60,"name":46,"description":61,"armGroupLabels":62,"otherNames":37},"DRUG","QLS32015 will be administered subcutaneously.",[46],{"type":60,"name":64,"description":65,"armGroupLabels":66,"otherNames":37},"Pomalidomide","Pomalidomide will be administered orally.",[52],{"type":60,"name":68,"description":69,"armGroupLabels":70,"otherNames":37},"Selinexor","Selinexor will be administered orally.",[52],{"type":60,"name":72,"description":73,"armGroupLabels":74,"otherNames":37},"Dexamethasone","Dexamethasone will be administered orally",[52],[76],{"name":77,"role":78,"phone":79,"phoneExt":37,"email":80},"Gang An, Professor","CONTACT","008613502181109","angang@ihcams.ac.cn",[82],{"facility":83,"status":84,"city":85,"state":86,"zip":37,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"National Clinical Research Center for Blood Diseases","RECRUITING","Tianjin","Tianjin Municipality","China","CN",{"type":90,"coordinates":91},"Point",[92,93],117.17667,39.14222,{"lat":93,"lon":92},[96],{"name":97,"role":78,"phone":98,"phoneExt":37,"email":99},"Qirou Wang","86 022 23608025","ec@ihcams.ac.cn",{"type":101,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100603568",false,"NCT07138209","A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 3 Randomized Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥18 years old, regardless of gender.\n* Subjects should be willing and able to comply with the study schedule and protocols.\n* Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria.Must have measurable disease as defined by the following: Serum M-protein greater than or equal to 0.5 g\u002FdL; OR Urine M-protein greater than or equal to 200 mg\u002F24 hours; OR Serum free light chain (FLC) assay; involved FLC level greater than or equal to 10 mg\u002FdL provided the serum FLC ratio is abnormal.\n* Received at least 3 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody (mAb).\n\nExclusion Criteria:\n\n* Known hypersensitivity to any of the ingredients of this product.\n* Diagnosis of active plasma cell leukemia or systemic light chain amyloidosis.\n* Has any active severe mental illness, medical illness, or other symptoms\u002Fconditions that may affect treatment, compliance, or the ability to provide informed consent, as determined by the investigator.\n* Disease is considered refractory to pomalidomide and selinexor.","ALL","18 Years",{"count":111,"type":112},228,"ESTIMATED","INTERVENTIONAL",[115],"PHASE3","The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd\u002FSd for the treatment of relapsed or refractory multiple myeloma.",[118],"Relapsed or Refractory Multiple Myeloma","2026-05-20",{"date":121,"type":122},"2026-05-22","ACTUAL",{"date":124,"type":122},"2025-11-07",{"date":126,"type":112},"2029-12",{"name":5,"class":6},1]